Robert K Koenekoop1, Ruifang Sui2, Juliana Sallum3, L Ingeborgh van den Born4, Radwan Ajlan5, Ayesha Khan5, Anneke I den Hollander6, Frans P M Cremers7, Janine D Mendola8, Ava K Bittner9, Gislin Dagnelie9, Ronald A Schuchard10, David A Saperstein11. 1. McGill Ocular Genetics Laboratory and Paediatric Ophthalmology, Montreal Children's Hospital, Departments of Paediatric Surgery, Human Genetics and Ophthalmology, McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: robert.koenekoop@mcgill.ca. 2. Ophthalmology, Peking Union Medical College Hospital, Beijing, China. 3. Ophthalmology, Federal University of São Paulo, São Paulo, Brazil. 4. Medical Retina, Rotterdam Eye Hospital, Rotterdam, Netherlands. 5. McGill Ocular Genetics Laboratory and Paediatric Ophthalmology, Montreal Children's Hospital, Departments of Paediatric Surgery, Human Genetics and Ophthalmology, McGill University Health Centre, Montreal, Quebec, Canada. 6. Department of Ophthalmology, Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands. 7. Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands. 8. McGill Vision Research Unit and Department of Ophthalmology, McGill University Health Centre, Montreal, Quebec, Canada. 9. The Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. 10. Neurosurgery, Stanford University, CA, USA. 11. Vitreoretinal Associates of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Leber congenital amaurosis, caused by mutations in RPE65 and LRAT, is a severe form of inherited retinal degeneration leading to blindness. We aimed to assess replacement of the missing chromophore 11-cis retinal with oral QLT091001 (synthetic 9-cis-retinyl acetate) in these patients. METHODS: In our open-label, prospective, phase 1b trial, we enrolled patients (aged ≥6 years) with Leber congenital amaurosis and RPE65 or LRAT mutations at McGill University's Montreal Children's Hospital. Patients received 7 days of oral QLT091001 (10-40 mg/m(2) per day). We assessed patients at baseline and days 7, 9, 14, and 30, and then 2 months and every 2 months thereafter for up to 2·2 years for safety outcomes and visual function endpoints including Goldmann visual fields (GVF), visual acuity, and functional MRI assessment. We regarded patients as having an improvement in vision if we noted at least a 20% improvement in retinal area on GVF compared with baseline or a visual acuity improvement of five or more letters compared with baseline in two consecutive study visits (or any improvement from no vision at baseline). This study is registered with ClinicalTrials.gov, number NCT01014052. FINDINGS: Between December, 2009, and June, 2011, we enrolled and treated 14 patients aged 6-38 years who were followed up until March, 2012. Ten (71%) of 14 patients had an improvement in GVF areas (mean increase in retinal area of 28-683%). Six (43%) patients had an improvement in visual acuity (mean increase of 2-30 letters). Self-reported or parent-reported improvements in activities of daily living supported these findings. After 2 years, 11 (79%) patients had returned to their baseline GVF retinal area and ten (71%) had returned to baseline visual acuity letter values. Thus, three (21%) patients had a sustained GVF response and four (30%) had a sustained visual acuity response. Four patients had functional MRI scans, which correlated with visual response or absence of response to treatment. No serious adverse events occurred, although we noted transient headaches (11 patients), photophobia (11 patients), reduction in serum HDL concentrations (four patients), and increases in serum triglycerides (eight patients) and aspartate aminotransferase concentrations (two patients). INTERPRETATION: Non-invasive oral QLT091001 therapy is well tolerated, and can rapidly improve visual function in some patients with Leber congenital amaurosis and RPE65 and LRAT mutations. FUNDING: QLT, Foundation Fighting Blindness Canada, CIHR, FRSQ, Reseau Vision.
BACKGROUND:Leber congenital amaurosis, caused by mutations in RPE65 and LRAT, is a severe form of inherited retinal degeneration leading to blindness. We aimed to assess replacement of the missing chromophore 11-cis retinal with oral QLT091001 (synthetic 9-cis-retinyl acetate) in these patients. METHODS: In our open-label, prospective, phase 1b trial, we enrolled patients (aged ≥6 years) with Leber congenital amaurosis and RPE65 or LRAT mutations at McGill University's Montreal Children's Hospital. Patients received 7 days of oral QLT091001 (10-40 mg/m(2) per day). We assessed patients at baseline and days 7, 9, 14, and 30, and then 2 months and every 2 months thereafter for up to 2·2 years for safety outcomes and visual function endpoints including Goldmann visual fields (GVF), visual acuity, and functional MRI assessment. We regarded patients as having an improvement in vision if we noted at least a 20% improvement in retinal area on GVF compared with baseline or a visual acuity improvement of five or more letters compared with baseline in two consecutive study visits (or any improvement from no vision at baseline). This study is registered with ClinicalTrials.gov, number NCT01014052. FINDINGS: Between December, 2009, and June, 2011, we enrolled and treated 14 patients aged 6-38 years who were followed up until March, 2012. Ten (71%) of 14 patients had an improvement in GVF areas (mean increase in retinal area of 28-683%). Six (43%) patients had an improvement in visual acuity (mean increase of 2-30 letters). Self-reported or parent-reported improvements in activities of daily living supported these findings. After 2 years, 11 (79%) patients had returned to their baseline GVF retinal area and ten (71%) had returned to baseline visual acuity letter values. Thus, three (21%) patients had a sustained GVF response and four (30%) had a sustained visual acuity response. Four patients had functional MRI scans, which correlated with visual response or absence of response to treatment. No serious adverse events occurred, although we noted transient headaches (11 patients), photophobia (11 patients), reduction in serum HDL concentrations (four patients), and increases in serum triglycerides (eight patients) and aspartate aminotransferase concentrations (two patients). INTERPRETATION: Non-invasive oral QLT091001 therapy is well tolerated, and can rapidly improve visual function in some patients with Leber congenital amaurosis and RPE65 and LRAT mutations. FUNDING: QLT, Foundation Fighting Blindness Canada, CIHR, FRSQ, Reseau Vision.
Authors: Galuh D N Astuti; Mette Bertelsen; Markus N Preising; Muhammad Ajmal; Birgit Lorenz; Sultana M H Faradz; Raheel Qamar; Rob W J Collin; Thomas Rosenberg; Frans P M Cremers Journal: Eur J Hum Genet Date: 2015-12-02 Impact factor: 4.246
Authors: Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire Journal: Lancet Date: 2017-07-14 Impact factor: 79.321
Authors: Michael P Barry; Ava K Bittner; Liancheng Yang; Rebecca Marcus; Mian Haris Iftikhar; Gislin Dagnelie Journal: Optom Vis Sci Date: 2016-07 Impact factor: 1.973
Authors: Vaidehi S Dedania; Jerry Y Liu; Dana Schlegel; Chris A Andrews; Kari Branham; Naheed W Khan; David C Musch; John R Heckenlively; K Thiran Jayasundera Journal: Ophthalmic Genet Date: 2017-07-13 Impact factor: 1.803
Authors: Artur V Cideciyan; Geoffrey K Aguirre; Samuel G Jacobson; Omar H Butt; Sharon B Schwartz; Malgorzata Swider; Alejandro J Roman; Sam Sadigh; William W Hauswirth Journal: Invest Ophthalmol Vis Sci Date: 2014-12-23 Impact factor: 4.799
Authors: Sylwia Chelstowska; Made Airanthi K Widjaja-Adhi; Josie A Silvaroli; Marcin Golczak Journal: Biochemistry Date: 2017-08-15 Impact factor: 3.162